A Russian company, specialized in diagnostic services, is engaged in the development and implementation of diagnostic devices – rapid blood tests based on innovative bio- and IT-technologies. The company uses the most advanced technologies of Russian production. The company is looking for partners to conclude distribution service agreements with.
The company was founded in 2014 in the Republic of Buryatia, Russia. The company’s engineers have extensive experience in the development of express diagnostics for healthcare.
The main activity of the company is the development of express tests in Russia. Its goal is to create affordable and accurate express diagnostics for healthcare. The team consists of professionals in the field of biotechnology, rapid test development and production. The bio laboratory and production facilities are certified according to the ISO 13485 standard.
The company develops fast and accurate rapid tests for diagnostics. It has also developed a rapid test for antibodies to COVID-19. The test is intended for the qualitative determination of IgG and IgM antibodies to SARS-CoV-2 in serum, plasma or whole blood.
Type and Role of Partner Sought
Type: The company intends to sell its blood tests abroad in the United States, Europe and Japan. The company has a plan to place the production of hemotests in Buryatia to sell them to China, as well as to find a buyer from Big Pharma to promote the product in global markets. The main potential partners are: structures of the Ministry of Health, hospitals, hospitals, scientific and medical centers, clinical diagnostic laboratories (public and private).
Role: Under the distribution agreement, the Russian company will supply the necessary equipment to the partner for the subsequent sale.
In addition, the company develops rapid tests for the diagnosis of ischemic stroke and traumatic brain injury based on key biomarkers of brain damage.
The main product is:
Antibodies to NR2 – a biomarker of brain ischemia
The test for antibodies to NR2 allows diagnosing the presence and degree of chronic cerebral ischemia at the preclinical level.
An anti-NR2 antibody test is recommended for assessing the risk of acute ischemic stroke in patients with risk factors:
• arterial hypertension (> 140/90 mm Hg),
• atrial fibrillation,
• dyslipidaemia (cholesterol> 5.2 mmol / L, LDL> 2.5 mmol / L),
• estrogenic use
• and patients with previous ischemic stroke.
The NR2 antibody test can also be used in vascular surgery to assess the risk of early postoperative neurological complications.
The company has developed a rapid blood test to detect stroke and other brain damage. For this, about 150 million rubles were collected. Currently, the start-up is conducting another round of investments, during which it is going to raise another $2.5 million for clinical trials and bringing the product to the markets of Russia and Europe.
The company intends to sell its blood tests abroad: in the United States, Europe and Japan. The company has a plan to place the production of hemotests in Buryatia to sell them to China, as well as to find a buyer from Big Pharma to promote the product in global markets.
The company wants to expand abroad with growing production and therefore they wish to find new partners – distributors, capable to roll out the products on their markets, based on distribution agreements.
Advantages and Innovations
Advantages of the company:
– high quality of research due to a well-established system of work, which ensures high reliability;
– use of the best technologies of Russian production.
– unlike others who conduct similar research on biomarkers, the company provides a serial product sample, its clinical trials and registration.
Stage of Development Already on the market
IPR status: Secret Know-how
Contact Person: Jana Vavrinova
Phone Number +34 981 337 146